ORIC
ORIC Pharmaceuticals, Inc. NASDAQ Listed Apr 24, 2020$8.81
Mkt Cap $912.0M
52w Low $4.54
41.1% of range
52w High $14.93
50d MA $11.12
200d MA $10.98
P/E (TTM)
-6.7x
EV/EBITDA
-5.3x
P/B
2.2x
Debt/Equity
0.0x
ROE
-33.7%
P/FCF
-6.3x
RSI (14)
—
ATR (14)
—
Beta
1.36
50d MA
$11.12
200d MA
$10.98
Avg Volume
1.9M
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
240 East Grand Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -0.31 | -0.34 | -9.7% | 9.63 | -2.3% | -0.6% | -3.4% | -8.5% | — | — | — |
| Feb 23, 2026 | AMC | -0.34 | -0.30 | +11.8% | 11.71 | +3.2% | +14.6% | +14.4% | +15.3% | +14.9% | +18.5% | — |
| Nov 13, 2025 | AMC | -0.41 | -0.33 | +19.5% | 12.19 | +2.1% | +0.5% | -1.1% | -2.4% | -5.8% | -5.8% | — |
| Aug 12, 2025 | AMC | -0.46 | -0.47 | -2.2% | 9.52 | +0.4% | +3.3% | +4.3% | +1.5% | +4.0% | +0.8% | — |
| May 5, 2025 | AMC | -0.51 | -0.42 | +17.6% | 5.70 | +2.3% | -11.6% | -17.5% | -6.7% | -10.9% | -5.1% | — |
| Feb 18, 2025 | AMC | -0.52 | -0.51 | +1.9% | 7.85 | +9.2% | +1.1% | -4.8% | -2.2% | -3.7% | +2.9% | — |
| Nov 12, 2024 | AMC | -0.48 | -0.49 | -2.1% | 10.26 | -0.3% | +0.1% | -13.9% | -17.2% | -16.6% | -13.4% | — |
| Aug 12, 2024 | AMC | -0.42 | -0.45 | -7.1% | 8.28 | -0.2% | +6.8% | +19.2% | +30.8% | +12.3% | +22.0% | — |
| May 6, 2024 | AMC | -0.44 | -0.37 | +15.9% | 9.37 | +0.7% | +2.6% | +2.5% | +1.4% | -4.1% | -4.3% | — |
| Mar 11, 2024 | AMC | -0.49 | -0.49 | +0.0% | 14.99 | -2.4% | -4.5% | +1.6% | +0.2% | +0.7% | -2.1% | — |
| Nov 6, 2023 | AMC | -0.46 | -0.44 | +4.3% | 6.90 | -1.4% | -0.7% | -1.4% | -6.8% | -9.6% | -11.2% | — |
| Aug 10, 2023 | AMC | -0.58 | -0.50 | +13.8% | 7.93 | +7.9% | +11.0% | +0.9% | +10.1% | +16.5% | +7.3% | — |
| May 8, 2023 | AMC | -0.54 | -0.53 | +1.9% | 5.22 | -2.1% | -2.5% | -1.5% | -1.0% | -2.0% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.48 | $7.25 | -3.1% | +18.9% | +19.1% | +18.6% | +21.0% | +38.8% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $12.67 | $10.25 | -19.1% | -41.0% | -29.8% | -29.7% | -30.0% | -28.6% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.76 | $11.96 | +1.7% | +1.2% | +3.9% | +2.6% | -7.7% | -5.6% |
| Feb 24 | Wedbush | Maintains | Outperform → Outperform | — | $11.71 | $12.08 | +3.2% | +14.6% | +14.4% | +15.3% | +14.9% | +18.5% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.71 | $12.08 | +3.2% | +14.6% | +14.4% | +15.3% | +14.9% | +18.5% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $11.71 | $12.08 | +3.2% | +14.6% | +14.4% | +15.3% | +14.9% | +18.5% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $9.15 | $9.07 | -0.9% | +10.8% | +23.0% | +25.9% | +32.5% | +27.0% |
| Dec 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.00 | $12.37 | +12.5% | -4.4% | -7.8% | -9.1% | -11.9% | -14.7% |
| Dec 8 | Wedbush | Maintains | Outperform → Outperform | — | $11.00 | $12.37 | +12.5% | -4.4% | -7.8% | -9.1% | -11.9% | -14.7% |
| Nov 18 | JP Morgan | Maintains | Overweight → Overweight | — | $12.06 | $11.93 | -1.1% | -1.3% | -4.8% | -4.8% | -3.6% | -2.2% |
| Nov 17 | Citigroup | Maintains | Buy → Buy | — | $12.25 | $12.29 | +0.3% | -1.6% | -2.9% | -6.3% | -6.3% | -5.1% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.1% | -2.4% | -5.8% | -5.8% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.1% | -2.4% | -5.8% | -5.8% |
| Nov 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $12.19 | $12.44 | +2.1% | +0.5% | -1.1% | -2.4% | -5.8% | -5.8% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $9.83 | $9.55 | -2.8% | +1.0% | -1.7% | +0.7% | -2.3% | -3.3% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.83 | $9.55 | -2.8% | +1.0% | -1.7% | +0.7% | -2.3% | -3.3% |
| Aug 13 | Guggenheim | Maintains | Buy → Buy | — | $9.52 | $9.56 | +0.4% | +3.3% | +4.3% | +1.5% | +4.0% | +0.8% |
| May 19 | JP Morgan | Maintains | Overweight → Overweight | — | $4.73 | $4.67 | -1.3% | +8.7% | +19.9% | +24.1% | +25.8% | +34.2% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.32 | $5.34 | +0.4% | -4.5% | +1.7% | -0.2% | -8.5% | -10.9% |
| May 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.70 | $5.83 | +2.3% | -11.6% | -17.5% | -6.7% | -10.9% | -5.1% |
| May 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.70 | $5.83 | +2.3% | -11.6% | -17.5% | -6.7% | -10.9% | -5.1% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.67 | $5.64 | -0.5% | +0.5% | -11.1% | -17.1% | -6.2% | -10.4% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $8.08 | $8.50 | +5.2% | +2.7% | -3.0% | -0.6% | -5.4% | -5.2% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $8.08 | $8.50 | +5.2% | +2.7% | -3.0% | -0.6% | -5.4% | -5.2% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.08 | $8.50 | +5.2% | +2.7% | -3.0% | -0.6% | -5.4% | -5.2% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $7.69 | +0.1% | -1.6% | +5.2% | +8.1% | +2.1% | +4.6% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.47 | $7.69 | +2.9% | +2.8% | +1.2% | +8.2% | +11.1% | +5.0% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.23 | $11.72 | +4.4% | -12.3% | -15.9% | -26.4% | -25.6% | -30.1% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $12.25 | $12.31 | +0.5% | -8.3% | -19.6% | -22.9% | -32.5% | -31.8% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $12.39 | $12.67 | +2.3% | +1.2% | -1.1% | -9.4% | -20.5% | -23.7% |
| Jan 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.60 | $8.92 | +3.7% | +15.2% | +26.4% | +16.7% | +11.4% | +16.3% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.96 | $8.71 | +9.4% | +8.0% | +24.5% | +36.6% | +26.1% | +20.4% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.41 | $9.40 | -0.1% | +0.7% | +2.9% | +9.5% | +5.7% | +9.0% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.10 | $10.14 | +0.4% | +5.6% | +10.5% | +11.4% | +6.2% | +6.4% |
| Sep 10 | Wedbush | Maintains | Outperform → Outperform | — | $9.79 | $9.80 | +0.1% | +1.7% | +1.1% | -7.5% | +1.0% | +2.0% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.84 | $8.87 | +0.3% | +11.7% | +22.5% | +5.2% | +14.3% | +11.5% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $8.28 | $8.26 | -0.2% | +6.8% | +19.2% | +30.8% | +12.3% | +22.0% |
| Aug 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.28 | $8.26 | -0.2% | +6.8% | +19.2% | +30.8% | +12.3% | +22.0% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.99 | $11.63 | +5.8% | -7.0% | -7.0% | -7.0% | -2.7% | +2.5% |
| Jul 17 | Wedbush | Maintains | Outperform → Outperform | — | $10.99 | $11.63 | +5.8% | -7.0% | -7.0% | -7.0% | -2.7% | +2.5% |
| Jul 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $9.34 | $9.49 | +1.6% | -0.1% | +2.8% | +7.7% | +15.1% | +17.7% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $9.37 | $9.44 | +0.7% | +2.6% | +2.5% | +1.4% | -4.1% | -4.3% |
| Mar 27 | JP Morgan | Maintains | Overweight → Overweight | — | $13.46 | $13.54 | +0.6% | +0.1% | +2.2% | -3.9% | -9.6% | -15.4% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.36 | $15.16 | +5.6% | +1.6% | -3.1% | -6.3% | -6.3% | -6.2% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +1.6% | +0.2% | +0.7% | -2.1% |
| Mar 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +1.6% | +0.2% | +0.7% | -2.1% |
| Mar 12 | Baird | Maintains | Outperform → Outperform | — | $14.99 | $14.63 | -2.4% | -4.5% | +1.6% | +0.2% | +0.7% | -2.1% |
| Mar 1 | Wedbush | Maintains | Outperform → Outperform | — | $12.74 | $13.57 | +6.5% | +15.1% | +17.4% | +21.6% | +25.8% | +24.9% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.65 | $8.70 | +0.6% | +8.1% | +6.1% | +7.6% | -1.7% | +1.0% |
| Oct 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.00 | $6.07 | +1.2% | +8.0% | +4.7% | +6.2% | +11.7% | +9.5% |
No insider trades available.
8-K
Unknown — 8-K Filing
ORIC is restating standard forward-looking statement disclaimers in an 8-K, suggesting material developments that require disclosure but no immediate operational changes warrant investor concern absent additional specifics.
Mar 31
8-K
Oric Pharmaceuticals, Inc. -- 8-K Filing
Oric Pharmaceuticals filed a prospectus supplement indicating preparation for a future securities offering, though no immediate sale has occurred or been announced.
Feb 23
8-K
Oric Pharmaceuticals, Inc. -- 8-K Filing
Oric Pharmaceuticals reported positive 2025 clinical data for lead candidates rinzimetostat in prostate cancer and enozertinib in lung cancer, potentially supporting its oncology pipeline advancement.
Feb 23
Data updated apr 26, 2026 5:51pm
· Source: massive.com